Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.42 |
| ▸ | TP53 | P04637 | 8/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2445362 | 0.84 | MAPT (0.43) | MAPTTP53LMNARXFP1SMN1; SMN2 | |
| SCHEMBL496230 | 0.84 | MAPT (0.43) | MAPTTP53LMNARXFP1SMN1; SMN2 | |
| SCHEMBL496256 | 0.79 | HIF1A (0.50) | — | |
| SCHEMBL3674264 | 0.77 | CNR1 (0.37) | MAPTLMNASMN1; SMN2 | |
| SCHEMBL496214 | 0.72 | HCRTR1 (0.40) | TP53LMNA | |
| SCHEMBL2442435 | 0.72 | HCRTR1 (0.40) | TP53LMNA | |
| SCHEMBL24898755 | 0.69 | MAPT (0.60) | MAPTTP53LMNARXFP1SMN1; SMN2 | |
| SCHEMBL14748054 | 0.69 | HTR1A (0.48) | MAPTTP53 | |
| SCHEMBL497068 | 0.68 | HPGD (0.41) | TP53SMN1; SMN2 | |
| SCHEMBL496159 | 0.67 | HTR4 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106215-B2 | 3-aza-bicyclo[3.3.0]octane compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-31 | — | — | US | disclosed |
| US-8106215-B2 | 3-aza-bicyclo[3.3.0]octane compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-31 | — | — | US | disclosed |
| US-8106215-B2 | 3-aza-bicyclo[3.3.0]octane compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-31 | — | — | US | disclosed |
| EP-2164847-B1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | HCRTR2, HCRTR1, OXTR | MAPT 3260/4885TP53 4826/4885LMNA 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.